Journal article icon

Journal article

A randomized, double‐blind, placebo‐controlled trial of camicinal in Parkinson's disease

Abstract:

Background: Delayed gastric emptying may impair ʟ-dopa absorption, contributing to motor fluctuations. We evaluated the effect of camicinal (GSK962040), a gastroprokinetic, on the absorption of ʟ-dopa and symptoms of PD.

Methods: Phase II, double‐blind, placebo‐controlled trial. Participants were randomized to receive camicinal 50 mg once‐daily (n = 38) or placebo (n = 20) for 7 to 9 days.

Results: ʟ-dopa exposure was similar...

Expand abstract
Publication status:
Published
Peer review status:
Peer reviewed

Actions


Access Document


Files:
Publisher copy:
10.1002/mds.27259

Authors


More by this author
Role:
Author
ORCID:
0000-0002-1338-1290
Expand authors...
GlaxoSmithKline More from this funder
Michael J. Fox Foundation More from this funder
Parkinsonfonden More from this funder
Publisher:
Wiley Publisher's website
Journal:
Movement Disorders Journal website
Volume:
33
Issue:
2
Pages:
329-332
Publication date:
2017-12-26
Acceptance date:
2017-11-05
DOI:
EISSN:
1531-8257
ISSN:
0885-3185
Pmid:
29278279
Source identifiers:
1033403

Terms of use


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP